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ABSTRACT
In total, 408 staphylococcal isolates were tested
for inducible clindamycin resistance (ICR) by
the disk-diffusion induction test (D-test). ICR
was detected in 5.7% of 105 methicillin-resistant
Staphylococcus aureus (MRSA) isolates, 3.6% of
111 methicillin-susceptible S. aureus isolates,
30.8% of 94 methicillin-resistant coagulase-negat-
ive staphylococcal (CoNS) isolates, and 11.2% of
98 methicillin-sensitive CoNS isolates. All MRSA
isolates that were erythromycin-resistant and
clindamycin-susceptible were positive by the
D-test. The same results were obtained with an
azithromycin instead of an erythromycin disk.
All isolates were susceptible to quinupristin–
dalfopristin. The cost–benefit of the D-test
should be evaluated locally after determining
the incidence of the different resistance pheno-
types.
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Resistance to macrolides in Staphylococcus aureus
and coagulase-negative staphylococci (CoNS)
may result either from an active efflux mechanism
or a ribosomal target modification; the latter is the
most common mechanism of acquired resistance
to macrolides, lincosamides and streptogramin B
(MLSB) antibiotics in staphylococci [1,2]. MLSB
resistance can be either constitutive (MLSBc) or
inducible (MLSBi). The erythromycin resistance
methylase (erm) genes encode enzymes that con-
fer inducible or constitutive resistance to MLSB
agents [3]. Constitutively-resistant isolates are
resistant to all MLSB antibiotics and are detected
readily by standard susceptibility testing meth-
ods. Inducible resistance is expressed in the
presence of strong inducers of methylase synthe-
sis, such as 14-membered (e.g., erythromycin) and
15-membered (e.g., azithromycin) macrolides.
The 16-membered macrolides (e.g., spiramy-
cin), lincosamides (e.g., clindamycin) and strep-
togramin B antibiotics may appear active when
their susceptibility is tested by standard methods,
as they are only weak inducers of methylase
synthesis, but inducible resistance can be detected
by the disk-diffusion induction test (D-test) [4].
This test involves the placement, 15 mm apart
from centre to centre, of an erythromycin disk and
a clindamycin disk on a plate of Mueller–Hinton
agar (MHA) [1,2,4]. As erythromycin diffuses
through the agar, resistance to clindamycin is
induced, resulting in a ‘flattening’ or ‘blunting’ of
the clindamycin zone of inhibition adjacent to the
erythromycin disk, giving a D-shape to the zone
(D-zone effect) [1]. The phenotypic characteristics
of isolates are indicative of the probable resistance
mechanism; that is, an erythromycin-resistant
(ER-R) and clindamycin-resistant (CL-R) pheno-
type indicates MLSBc resistance, while an ER-R
CL-S phenotype indicates either the MLSBi resist-
ance phenotype or an active efflux pump resist-
ance mechanism [1,2].
The purpose of the present study was to
determine the incidence of inducible clindamycin
resistance among staphylococci in a university
hospital in Turkey. In total, 408 staphylococcal
isolates obtained from consecutive clinical speci-
mens were included in the study, comprising 105
methicillin-resistant Staphylococcus aureus (MRSA)
isolates, 111 methicillin-sensitive S. aureus (MSSA)
isolates and 192 CoNS isolates, 94 of which were
methicillin-resistant. The isolates were tested for
susceptibility to clindamycin (2 lg), erythromycin
(15 lg), azithromycin (15 lg) and quinupristin–
dalfopristin (15 lg) disks, according to NCCLS
criteria [5]. Quality control was performed with
S. aureus strain ATCC 25923; inhibition zone
diameters were in the ranges stipulated by the
NCCLS [5].
Isolates that were CL-S and ER-R were tested
for inducible resistance by the D-test. Clindamycin
and erythromycin disks were placed 15 mm apart
from centre to centre on MHA plates. On a
separate MHA plate, azithromycin disks were
placed 15 mm apart from erythromycin disks to
investigate whether the erythromycin ⁄ clindamy-
cin and azithromycin ⁄ clindamycin induction
results were comparable. Results were read after
incubation for 18 h at 35C. If an isolate was ER-R
and CL-S, with a D-shaped inhibition zone around
the clindamycin disk, it was considered to be
positive for inducible resistance (D-test positive).
If the isolate was ER-R and CL-S, but with both
zones of inhibition showing a circular shape, the
isolate was considered to be negative for indu-
cible resistance (D-test negative), but to have an
active efflux pump. If the isolate was ER-R and
CL-R, the isolate was considered to have an
MLSBc phenotype [1,2,6]. The results for azithro-
mycin were evaluated in the same manner as
those for erythromycin. All antibiotic disks were
purchased from Oxoid (Basingstoke, UK).
Clindamycin susceptibility rates were 36.2%,
95.4%, 54.2% and 85.7% among MRSA, MSSA,
methicillin-resistant CoNS and methicillin-sus-
ceptible CoNS, respectively, by the standard disk
diffusion test [5]. Erythromycin (and also azith-
romycin) susceptibility rates were 30.4%, 88.2%,
10.6% and 59.1%, respectively. All 408 staphylo-
coccal isolates tested were susceptible to quin-
opristin–dalfopristin. All six MRSA isolates and
four of eight MSSA isolates with the ER-R CL-S
phenotype were D-test positive. Of 41 methicil-
lin-resistant CoNS and 26 methicillin-susceptible
CoNS isolates with the ER-R CL-S phenotype, 29
(70.7%) and 11 (42.3%), respectively, were D-test
positive. The same results were obtained by
using an azithromycin disk instead of an eryth-
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romycin disk. The results are summarised in
Table 1.
Clindamycin is a good alternative for the treat-
ment of both methicillin-resistant and -susceptible
staphylococcal infections, but therapeutic failures
caused by MLSBi resistance are being reported
more commonly. Accurate antimicrobial suscepti-
bility data are important for the management of
such infections [1], but false susceptibility results
may be obtained if isolates are not tested for
inducible clindamycin resistance [1]. Routine test-
ing of significant staphylococcal isolates for indu-
cible clindamycin resistance is recommended in
the 2004 NCCLS guidelines [6], while Siberry et al.
[7] advocate testing all S. aureus isolates for MLSBi
resistance in the case of surgical site infections
caused by ER-R CL-S isolates of MRSA that do not
respond to clindamycin treatment. Reports of
clindamycin treatment failures are accumulating
for patients infected with MLSBi isolates [4,6,7].
However, to consider all ER-R staphylococci as CL-
R would lead to the denial of an effective and safe
therapy for patients infected with isolates that have
only the macrolide efflux mechanism [6]. The
frequencies of the different resistance patterns
vary widely among clinical staphylococcal isolates
according to the patient group and geographical
location [1,2,8,9]. Therefore, routine testing also
helps to clearly identify those isolates that remain
susceptible to clindamycin despite macrolide
resistance, the other aim of routine screening [1,2].
The present study also found that an azithro-
mycin disk could be used instead of an erythro-
mycin disk for the detection of MLSBi resistance.
The incidence of inducible clindamycin resistance
is important in a setting where clindamycin is
prescribed empirically, and this incidence is
known to vary between hospitals [2]. Thus, the
prevalence should be determined in individual
settings. To the best of our knowledge, the present
study is the first report from Turkey on the
incidence of inducible clindamycin resistance
among staphylococci. Efflux-mediated resistance
was not detected among the MRSA isolates, as all
ER-R and CL-S isolates were positive by the
D-test. Similarly, there were no quinopristin–
dalfopristin-resistant staphylococci in this study.
Susceptibility to quinopristin–dalfopristin is
caused by the dalfopristin component of the drug,
which is actually streptogramin A, although the
drug also has a streptogramin B component
termed quinupristin [9]. The cost–benefit of
performing the D-test routinely for staphylococci
should be evaluated in each individual laboratory
setting after determining the incidence of the
MLSBi and MLSBc resistance phenotypes.
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Table 1. Incidence of inducible and constitutive resistance
to erythromycin and clindamycin among staphylococcal
isolates from Turkey
Phenotype
No. (%) of
MRSA
isolates
No. (%) of
MSSA
isolates
No. (%) of
MR-CoNS
isolates
No. (%) of
MS-CoNS
isolates
ER-S CL-S 32 (30.4) 98 (88.2) 10 (10.6) 58 (59.1)
ER-R CL-R 67 (64.0) 5 (4.6) 43 (45.8) 14 (14.3)
ER-R CL-S D+ 6 (5.7) 4 (3.6) 29 (30.8) 11 (11.2)
ER-R CL-S D– 0 (0) 4 (3.6) 12 (12.7) 15 (15.3)
Total 105 111 94 98
CL, clindamycin; CoNS, coagulase-negative staphylococci; D+, D-test positive; D–,
D-test negative; ER, erythromycin; MR-CoNS, methicillin-resistant CoNS; MS-CoNS,
methicillin-susceptible CoNS; MRSA, methicillin-resistant Staphylococcus aureus;
MSSA, methicillin-susceptible S. aureus.
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